Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.

Publication Type:

Journal Article


Transplantation, Volume 81, Issue 6, p.818-25 (2006)


Adolescent, Adult, Aged, Cyclosporine, Drug Administration Schedule, Female, Graft vs Host Disease, Hematologic Neoplasms, hematopoietic stem cell transplantation, Humans, Immunosuppressive Agents, Male, Middle Aged, RECURRENCE, Retrospective Studies, Time Factors


It is unknown whether the duration of systemic immunosuppressive treatment after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT) might influence the incidence, severity, timing, and/or corticosteroid-responsiveness of graft-versus-host disease (GVHD).